Indoco Remedies receives USFDA approval for Lacosamide Tablets Capital Market Last Updated at March 22, 2022 10:32 IST |
Used as an anticonvulsant drug Indoco Remedies received final approval from the United States Food & Drug Administration (USFDA) for Lacosamide Tablets USP 50 mg, 100 mg, 150 mg and 200 mg, the generic version of Vimpat Tablets of UCB, Inc. Lacosamide Tablets are indicated for the prevention and control of seizures. It is an anticonvulsant/antiepileptic drug. Powered by Capital Market - Live News |
|